In a patient with a post‑traumatic intertrochanteric or femoral neck fracture whose orthopedic surgery is delayed 2–4 days, what are the evidence‑based guidelines for pharmacologic thromboprophylaxis with low‑molecular‑weight heparin, including when to start, timing of the last pre‑operative dose, when to restart post‑operatively, and total duration of prophylaxis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Evidence-Based Thromboprophylaxis for Delayed Hip Fracture Surgery

For patients with post-traumatic hip fractures (intertrochanteric or femoral neck) awaiting surgery delayed 2–4 days, start prophylactic-dose LMWH (e.g., enoxaparin 40 mg daily or dalteparin 5000 IU daily) on admission or as soon as possible after injury, give the last dose on the morning of the day before surgery (approximately 24 hours pre-operatively at half the daily dose if using twice-daily regimens), restart prophylactic-dose LMWH 12 hours after low-bleed-risk procedures or 24 hours after higher-bleed-risk procedures (with therapeutic-dose delayed 48–72 hours if bridging was used), and continue for a minimum of 28–35 days post-operatively.


When to Start Anticoagulation

Start prophylactic LMWH on admission or as soon as possible after the fracture occurs, even before surgery. Hip fracture surgery guidelines explicitly recommend starting thromboprophylaxis "before or as soon as possible after surgery" for hip fracture patients 1. More importantly, a large Norwegian registry study of 20,241 hemiarthroplasties for femoral neck fractures demonstrated that preoperative start of LMWH significantly reduced mortality (RR 0.88, p<0.001) and reoperation rates (RR 0.84, p=0.04) compared to postoperative start, with no increase in bleeding complications or hematoma-related reoperations 2. This finding is critical: delaying thromboprophylaxis until after surgery increases the risk of death.

Dosing on Admission

  • Enoxaparin 40 mg subcutaneous once daily 3
  • Dalteparin 5000 IU subcutaneous once daily 3
  • Fondaparinux 2.5 mg subcutaneous once daily (alternative) 3

These are prophylactic doses, not therapeutic doses. The evidence supports standard prophylactic dosing rather than higher-intensity regimens for pre-operative thromboprophylaxis 4.


Timing of Last Pre-Operative Dose

Give the last dose of LMWH on the morning of the day before surgery (approximately 24 hours before the procedure). If using a twice-daily regimen (e.g., enoxaparin 30 mg BID for orthopedic surgery), give half the total daily dose at this time 5.

The 2022 American College of Chest Physicians guideline specifically recommends administering the last pre-operative LMWH bridging dose approximately 24 hours before surgery rather than 10–12 hours before 5. This timing allows adequate clearance while maintaining thromboprophylaxis coverage. Studies show that when LMWH is given 12 hours pre-operatively, >90% of patients have detectable anticoagulant effect at surgery, with 34% having therapeutic levels—potentially increasing bleeding risk 5.

Practical Algorithm for Last Dose

  • Surgery scheduled for 8 AM Wednesday: Give last LMWH dose on Tuesday morning (approximately 24 hours before)
  • If using twice-daily dosing: Give half the usual dose (e.g., enoxaparin 30 mg instead of 60 mg total daily)
  • If using once-daily dosing: Give the full prophylactic dose (e.g., enoxaparin 40 mg)

When to Restart Post-Operatively

Restart prophylactic-dose LMWH 12 hours after surgery for most hip fracture procedures, or 24 hours after surgery if there are specific bleeding concerns. The timing depends on surgical hemostasis and bleeding risk 5.

Post-Operative Restart Algorithm

For standard hip fracture surgery (hemiarthroplasty, ORIF):

  • 12 hours post-operatively: Restart prophylactic-dose LMWH (enoxaparin 40 mg daily or dalteparin 5000 IU daily) if hemostasis is adequate 3
  • This is considered a low-to-moderate bleed-risk procedure in most cases

For procedures with higher bleeding concern or inadequate hemostasis:

  • 24–48 hours post-operatively: Delay restart until hemostasis is confirmed 5
  • Consider mechanical prophylaxis (intermittent pneumatic compression) in the interim 3

If the patient was on therapeutic anticoagulation pre-injury (e.g., for atrial fibrillation) and required bridging:

  • 48–72 hours post-operatively: Resume therapeutic-dose LMWH only after adequate hemostasis 3, 5
  • Use prophylactic-dose LMWH in the first 24–48 hours as a bridge 5

Critical Caveat: Neuraxial Anesthesia

If spinal or epidural anesthesia was used, wait at least 12 hours after catheter removal before giving LMWH to reduce the risk of epidural hematoma 6. For patients receiving prophylactic-dose LMWH once daily, neuraxial catheter removal should occur at least 12 hours after the last dose, and the next dose should be delayed at least 4 hours after catheter removal 6.


Duration of Prophylaxis

Continue LMWH for a minimum of 28–35 days after hip fracture surgery. This extended duration is strongly recommended for hip fracture patients 1, 3, 4, 7.

Duration Guidelines

  • Minimum duration: 10–14 days for all major orthopedic surgery 3, 4
  • Recommended duration for hip fracture: 28–35 days (up to 5 weeks) 1, 3, 4, 7
  • Rationale: Hip fracture patients remain at elevated VTE risk well beyond hospital discharge due to continued immobility, advanced age, comorbidities, and trauma 4, 7

The 2012 ACCP guidelines (9th edition) specifically state: "For hip arthroplasty and hip fracture surgery, we recommend continuing thromboprophylaxis for a minimum of 10 days and up to 35 days" (Grade 1A recommendation) 4. The 2008 ACCP guidelines similarly recommend extending prophylaxis beyond 10 days and up to 35 days for hip fracture surgery 7.

Practical Implementation

  • At discharge: Prescribe LMWH to complete 28–35 days total from surgery
  • Patient/family education: Teach subcutaneous injection technique or arrange home health nursing
  • Alternative if LMWH not feasible: Warfarin (INR 2.0–3.0) can be used, though LMWH is preferred 1, 3
  • Rivaroxaban: 10 mg daily for 10–35 days is an alternative for orthopedic surgery, though less studied specifically for hip fracture 3

Special Considerations and Common Pitfalls

Renal Impairment

  • CrCl 30–50 mL/min: Reduce fondaparinux to 1.5 mg daily 3; consider dose adjustment for LMWH
  • CrCl <30 mL/min: Avoid fondaparinux; consider unfractionated heparin or reduced-dose LMWH with anti-Xa monitoring 8

Bleeding Risk vs. Thrombotic Risk

The Norwegian registry data definitively shows that preoperative LMWH does not increase bleeding complications compared to postoperative start 2. The mortality benefit of early thromboprophylaxis outweighs theoretical bleeding concerns in hip fracture patients.

Mechanical Prophylaxis

  • Add intermittent pneumatic compression (IPC) if pharmacologic prophylaxis is contraindicated due to active bleeding 3
  • Do not use mechanical methods alone unless pharmacologic prophylaxis is absolutely contraindicated 9, 3

Delay to Surgery

Patients with hip fracture face progressive mortality and morbidity with delays beyond 24–48 hours 10. Do not delay surgery solely to allow LMWH washout if the patient has been receiving prophylactic doses. The 24-hour pre-operative interval is sufficient for prophylactic-dose LMWH clearance 5.

Antiplatelet Medications

If the patient is taking clopidogrel or other antiplatelet agents, do not delay trauma surgery 11. LMWH should still be given for VTE prophylaxis, as antiplatelet agents do not prevent venous thromboembolism 11.


Summary Algorithm

  1. On admission: Start enoxaparin 40 mg SC daily (or dalteparin 5000 IU SC daily)
  2. Last pre-op dose: Morning of the day before surgery (~24 hours before)
  3. Post-operative restart: 12 hours after surgery (or 24 hours if bleeding concerns)
  4. Duration: Continue for 28–35 days total from surgery
  5. Monitor: Ensure adequate hemostasis before each dose; adjust for renal function

This approach is supported by the highest-quality evidence showing reduced mortality with preoperative thromboprophylaxis 2 and strong guideline recommendations for extended-duration prophylaxis in hip fracture patients 1, 3, 1, 4, 7.

References

Related Questions

When should venous thromboembolism prophylaxis be initiated after an above‑knee amputation?
What dose and timing should be used to initiate postoperative pharmacologic thromboprophylaxis?
Which anticoagulants are recommended for venous thromboembolism prophylaxis in a patient with a femoral fracture after surgery?
What are the criteria for prophylactic low‑molecular‑weight heparin (LMWH) (including indications, contraindications, dosing, and duration) in patients immobilized due to a tibial fracture?
When is it appropriate to start dalteparin for venous thromboembolism prophylaxis in a patient with traumatic brain injury, and what dosing and contraindications should be considered?
How should a patient with hypercalcemia (serum calcium 13 mg/dL) and markedly elevated uric acid (16 mg/dL) be managed?
What intravenous fluid orders (type, infusion rate, and total volume) should be entered for a patient with serum sodium 180 mEq/L, potassium 2.7 mEq/L, and chloride 146 mEq/L?
What is the safest sperm production booster for a 73-year-old male patient that will not increase prostate-specific antigen levels?
Should desmopressin (DDAVP) be administered to a patient with severe hypernatremia (serum sodium 180 mEq/L), hypokalemia (potassium 2.7 mEq/L), and chloride 146 mEq/L?
Can amiodarone be administered to a patient with existing liver failure?
In a patient with a brain tumor who has hypernatremia and hypokalemia, should desmopressin be administered to treat the hypernatremia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.